Home / Solutions / Biologics / Orthofix Biologics / Trinity Elite

Trinity Elite

Allograft with Viable Cells

Exclusively processed by MTF Biologics, Trinity Elite™ is an allograft that contains the three essential components needed to support bone formation: an osteoconductive scaffold, verified osteoinductive potential, and osteogenic cells such as viable adult mesenchymal stem cells (MSCs), osteoprogenitor cells (OPCs), and osteoblasts.1,2, 3 Trinity Elite can eliminate the need for harvesting autograft.

Key Features

  • A complete autograft bone graft substitute that provides the essential elements to support bone healing
  • Moldable and cohesive cortical fibers4
  • Minimum 70% cell viability with minimum cell counts of 750,000 cells per cc of which 250,000 are MSC, OPC, and other bone-forming cells
  • Cancellous granules contain endogenous cells and enhance packability
  • Compatible with O-Genesis™ and RAPID™ graft delivery systems
  • Osteoinductive potential is tested on every lot
  • 15+ years on the market, 350,000+ patients implanted

Follow Us on LinkedIn

Stay up to date on the latest news, education, and insights from Orthofix Biologics.

Connect with Orthofix Biologics

Connect With Our Team

Connect with a member of our team to learn more about our biologics portfolio and find the right solution for your fusion needs.

Your Name(Required)
Your Location
Your Role/Specialty(Required)
Email(Required)

What Biologics solution are you interested in?

Select any solution you would like more information on.
Select All That Apply(Required)
Consent(Required)
Consent

Footnotes

  1. Vanichkachorn J, et al. A prospective clinical and radiographic 12-month outcome study of patients undergoing single-level anterior cervical discectomy and fusion for symptomatic cervical degenerative disc disease utilizing a novel viable allogeneic, cancellous, bone matrix (trinity evolution™) with a comparison to historical controls. Eur Spine J, 2016.
  2. Wind, et al. Twelve-Month Results from a Prospective Clinical Study Evaluating the Efficacy and Safety of Cellular Bone Allograft in Subjects Undergoing Lumbar Spine Fusion. Neurology International, 2022; 14, pp. 875-883.
  3. Park, D. K. et al. (2023). Twenty-four-month interim results from a prospective, single-arm clinical trial evaluating the performance and safety of cellular bone allograft in patients undergoing lumbar spinal fusion. BMC musculoskeletal disorders, 24(1), 895.
  4. Martin, G. J., Jr, et al. (1999). New formulations of demineralized bone matrix as a more effective graft alternative in experimental posterolateral lumbar spine arthrodesis. Spine, 24(7), 637–645.

Instructions For Use